RPE65: Role in the visual cycle, human retinal disease, and gene therapy

Ophthalmic Genetics

Volumn 30, Issue 2, 2009, Pages 57-62

  Cai, Xue ^a   Conley, Shannon M ^a   Naash, Muna I ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Gene therapy; LCA; Retina; Retinal pigment epithelium; RPE65

Indexed keywords

COMPLEMENTARY DNA; EYE PROTEIN; HYDROLASE; PARVOVIRUS VECTOR; RETINA PIGMENT EPITHELIUM 65 PROTEIN; UNCLASSIFIED DRUG; VISUAL PIGMENT; CARRIER PROTEIN; RPE65 PROTEIN, HUMAN;

BLINDNESS; CLINICAL TRIAL; DOG; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EYE INFLAMMATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC MODEL; HUMAN; KNOCKOUT MOUSE; LEBER CONGENITAL AMAUROSIS; MOLECULAR CLONING; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RETINA CONE; RETINA DISEASE; RETINA DYSTROPHY; RETINA ROD; RETINITIS PIGMENTOSA; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA DEGENERATION; VISION;

ANIMALIA;

ANIMALS; BLINDNESS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DOGS; EYE PROTEINS; GENE THERAPY; HUMANS; MICE; RETINAL DEGENERATION; VISION, OCULAR;

EID: 65449139573     PISSN: 13816810     EISSN: 17445094     Source Type: Journal    
DOI: 10.1080/13816810802626399     Document Type: Review

References (65)

1. Travis GH, Golczak M, Moise AR, et al.Diseases caused by defects in the visual cycle: Retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol. 2007;47:469-512.
2. Bavik CO, Busch C, Eriksson U. Characterization of a plasma retinol-binding protein membrane receptor expressed in the retinal pigment epithelium. J Biol Chem. 1992;267:23035-23042.
3. Redmond TM, Yu S, Lee E, et al. Rpe65 is necessary for production of 11-cis-vitamin a in the retinal visual cycle. Nat Genet. 1998;20:344-351.
4. Hamel CP, Tsilou E, Pfeffer BA, et al. Molecular cloning and expression of rpe65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J Biol Chem. 1993;268:15751-15757.
5. Nicoletti A,Wong DJ, Kawase K, et al. Molecular characterization of the human gene encoding an abundant 61 kda protein specific to the retinal pigment epithelium. Hum Mol Genet. 1995;4:641-649.
6. Hamel CP, Tsilou E, Harris E, et al. A developmentally regulated microsomal protein specific for the pigment epithelium of the vertebrate retina. Journal of neuroscience research. 1993;34:414-425.
7. Bavik CO, Levy F, Hellman U, et al. The retinal pigment epithelial membrane receptor for plasma retinol-binding protein. Isolation and cdna cloning of the 63-kda protein. The Journal of biological chemistry. 1993;268:20540-20546.
8. Hamel CP, Jenkins NA, Gilbert DJ, et al. The gene for the retinal pigment epithelium-specific protein rpe65 is localized to human 1p31 and mouse 3. Genomics. 1994;20:509-512.
9. Aguirre GD, Baldwin V, Pearce-Kelling S, et al. Congenital stationary night blindness in the dog: Common mutation in the rpe65 gene indicates founder effect. Mol Vis. 1998;4:23.
10. Manes G, Leducq R, Kucharczak J, et al. Rat messenger rna for the retinal pigment epithelium-specific protein rpe65 gradually accumulates in two weeks from late embryonic days. FEBS Lett. 1998;423:133-137.
11. Gal A, Gu S, Bremser D, et al. Mutation spectrum of pre65 in autosomal recessive childhood-onset severe retinal destrophy. Invest Ophthalmol Vis Sci. 1998;39:S901.
12. Galbavy ES, Olson MD. Morphogenesis of rod cells in the retina of the albino rat: A scanning electron microscopic study. Anat Rec. 1979;195:707-717.
13. Xue L,Gollapalli DR,Maiti P, et al.Apalmitoylation switchmechanism in the regulation of the visual cycle. Cell. 2004;117:761-771.
14. Takahashi Y, Moiseyev G, Chen Y, et al. The roles of three palmitoylation sites of rpe65 in its membrane association and isomerohydrolase activity. Invest Ophthalmol Vis Sci. 2006;47:5191-5196.
15. Jin M, Yuan Q, Li S, et al. Role of lrat on the retinoid isomerase activity and membrane association of rpe65. The Journal of biological chemistry. 2007;282:20915-20924.
16. Jin M, Li S, Moghrabi WN, et al. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell. 2005;122:449-459.
17. Moiseyev G, Chen Y, Takahashi Y, et al. Rpe65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A. 2005;102:12413-12418.
18. Redmond TM, Poliakov E, Yu S, et al. Mutation of key residues of rpe65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:13658-13663.
19. Moiseyev G, Takahashi Y, Chen Y, et al. Rpe65 is an iron(ii)- dependent isomerohydrolase in the retinoid visual cycle. J Biol Chem. 2006;281:2835-2840.
20. Znoiko SL, Crouch RK, Moiseyev G, et al. Identification of the rpe65 protein in mammalian cone photoreceptors. Invest Ophthalmol Vis Sci. 2002;43:1604-1609.
21. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by rpe65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A. 2005;102:6177-6182.
22. Mata NL, Moghrabi WN, Lee JS, et al. Rpe65 is a retinyl ester binding protein that presents insoluble substrate to the isomerase in retinal pigment epithelial cells. J Biol Chem. 2004;279:635-643.
23. Seeliger MW, Grimm C, Stahlberg F, et al. New views on rpe65 deficiency: The rod system is the source of vision in a mouse model of leber congenital amaurosis. Nat Genet. 2001;29:70-74.
24. Feathers KL, Lyubarsky AL, Khan NW, et al. Nrl-knockout mice deficient in rpe65 fail to synthesize 11-cis retinal and cone outer segments. Invest Ophthalmol Vis Sci. 2008;49:1126-1135.
25. Wenzel A, Von Lintig J, Oberhauser V, et al. Rpe65 is essential for the function of cone photoreceptors in nrl-deficient mice. Invest Ophthalmol Vis Sci. 2007;48:534-542.
26. Thompson DA,Gal A.Vitamin a metabolism in the retinal pigment epithelium: Genes, mutations, and diseases. Prog Retin Eye Res. 2003;22:683-703.
27. MorimuraH, Fishman GA, Grover SA, et al.Mutations in the rpe65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:3088-3093.
28. Gu SM, Thompson DA, Srikumari CR, et al. Mutations in rpe65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nature genetics. 1997;17:194-197.
29. Aguirre GK, Komaromy AM, Cideciyan AV, et al. Canine and human visual cortex intact and responsive despite early retinal blindness from rpe65 mutation. PLoS Med. 2007;4:e230.
30. Chen Y, Moiseyev G, Takahashi Y, et al. Impacts of two point mutations of rpe65 from leber's congenital amaurosis on the stability, subcellular localization and isomerohydrolase activity of rpe65. FEBS Lett. 2006;580:4200-4204. (Pubitemid 44037595)
31. Takahashi Y, Chen Y, Moiseyev G, et al. Two point mutations of rpe65 from patients with retinal dystrophies decrease the stability of rpe65 protein and abolish its isomerohydrolase activity. J Biol Chem. 2006;281:21820-21826.
32. Samardzija M, Von Lintig J, Tanimoto N, et al. R91w mutation in rpe65 leads to milder early-onset retinal dystrophy due to the generation of low levels of 11-cis-retinal. Human molecular genetics. 2008;17:281-292.
33. Lorenz B, Poliakov E, Schambeck M, et al. A novel rpe65 hypomorph expands the clinical phenotype of rpe65 mutations. A comprehensive clinical and biochemical functional study. Investigative ophthalmology & visual science. 2008
34. Marlhens F, Griffoin JM, Bareil C, et al. Autosomal recessive retinal dystrophy associated with two novel mutations in the rpe65 gene. Eur J Hum Genet. 1998;6:527-531.
35. Nilsson SE, Wrigstad A, Narfstrom K. Changes in the dc electroretinogram in briard dogs with hereditary congenital night blindness and partial day blindness. Exp Eye Res. 1992;54:291-296.
36. Pang JJ, Chang B, HawesNL, et al. Retinal degeneration 12 (rd12): A new, spontaneously arising mouse model for human leber congenital amaurosis (lca). Mol Vis. 2005;11:152-162.
37. Rohrer B, Goletz P, Znoiko S, et al. Correlation of regenerable opsin with rod erg signal in rpe65-/- mice during development and aging. Invest Ophthalmol Vis Sci. 2003;44:310-315.
38. Ablonczy Z, Crouch RK, Goletz PW, et al. 11-cis-retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors. J Biol Chem. 2002;277:40491-40498.
39. Cottet S,Michaut L, BoissetG, et al. Biological characterization of gene response in rpe65-/- mouse model of leber's congenital amaurosis during progression of the disease. Faseb J. 2006;20:2036-2049.
40. Znoiko SL, Rohrer B, Lu K, et al. Downregulation of conespecific gene expression and degeneration of cone photoreceptors in the rpe65-/- mouse at early ages. Invest Ophthalmol Vis Sci. 2005;46:1473-1479.
41. Ekesten B, Gouras P, Salchow DJ. Ultraviolet and middle wavelength sensitive cone responses in the electroretinogram (erg) of normal and rpe65 -/- mice. Vision Res. 2001;41:2425-2433.
42. Chen Y, Moiseyev G, Takahashi Y, et al. Rpe65 gene delivery restores isomerohydrolase activity and prevents early cone loss in rpe65-/- mice. Invest Ophthalmol Vis Sci. 2006;47:1177-1184.
43. Pang JJ, Chang B, Kumar A, et al. Gene therapy restores visiondependent behavior as well as retinal structure and function in a mouse model of rpe65 leber congenital amaurosis. Mol Ther. 2006;13:565-572.
44. Veske A, Nilsson SE, Narfstrom K, et al. Retinal dystrophy of swedish briard/briard-beagle dogs is due to a 4-bp deletion in rpe65. Genomics. 1999;57:57-61.
45. Narfstrom K, Katz ML, Bragadottir R, et al. Functional and structural recovery of the retina after gene therapy in the rpe65 null mutation dog. Invest Ophthalmol Vis Sci. 2003;44:1663-1672.
46. Wrigstad A. Hereditary dystrophy of the retinna and the retinal pigment epithelium in a strain of briard dogs: A clinical, morphological and electrophysiological study. Linkoping Univ Med Dissertations. 1994;423:1-116.
47. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28:92-95.
48. Buch PK, Bainbridge JW, Ali RR. Aav-mediated gene therapy for retinal disorders: From mouse to man. Gene Ther. 2008;15:849-857.
49. Bemelmans AP, Kostic C, Cachafeiro M, et al. Lentiviral gene transfer-mediated cone vision restoration in rpe65 knockout mice. Adv Exp Med Biol. 2008;613:89-95.
50. Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transfer of rpe65 rescues survival and function of cones in a mouse model of leber congenital amaurosis. PLoS Med. 2006;3:e347.
51. Dejneka NS, Surace EM, Aleman TS, et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther. 2004;9:182-188.
52. Nusinowitz S, Ridder WH, 3rd, Pang JJ, et al. Cortical visual function in the rd12 mouse model of leber congenital amarousis (lca) after gene replacement therapy to restore retinal function. Vision Res. 2006;46:3926-3934.
53. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized aav2-mediated gene transfer. Mol Ther. 2008;16:458-465.
54. Lai CM, Yu MJ, Brankov M, et al. Recombinant adeno-associated virus type 2-mediated gene delivery into the rpe65-/- knockout mouse eye results in limited rescue. Genet Vaccines Ther. 2004;2:3.
55. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose raav-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005;12:1072-1082.
56. Jacobs JB, Dell'Osso LF, Hertle RW, et al. Eye movement recordings as an effectiveness indicator of gene therapy in rpe65-deficient canines: Implications for the ocular motor system. Invest Ophthalmol Vis Sci. 2006;47:2865-2875.
57. Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision in rpe65-deficient briard dogs using an aav serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 2007;14:292-303.
58. Narfstrom K, Katz ML, Ford M, et al. In vivo gene therapy in young and adult rpe65-/- dogs produces long-term visual improvement. J Hered. 2003;94:31-37.
59. Narfstrom K, Vaegan, Katz M, et al. Assessment of structure and function over a 3-year period after gene transfer in rpe65-/- dogs. Doc Ophthalmol. 2005;111:39-48.
60. Rolling F, Le Meur G, Stieger K, et al. Gene therapeutic prospects in early onset of severe retinal dystrophy: Restoration of vision in rpe65 briard dogs using an aav serotype 4 vector that specifically targets the retinal pigmented epithelium. Bull Mem Acad R Med Belg. 2006;161:497-508; discussion 508-1499
61. Jacobson SG, Acland GM, Aguirre GD, et al. Safety of recombinant adeno-associated virus type 2-rpe65 vector delivered by ocular subretinal injection. Mol Ther. 2006;13:1074-1084.
62. Jacobson SG, Boye SL, Aleman TS, et al. Safety in nonhuman primates of ocular aav2-rpe65, a candidate treatment for blindness in leber congenital amaurosis. Hum Gene Ther. 2006;17:845-858.
63. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in leber's congenital amaurosis. N Engl J Med. 2008;358:2231-2239.
64. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for rpe65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:15112-15117.
65. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.